The Development of a Precision Medicine Platform to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma

被引：0
|
作者：
Liu, Yang [1 ]
Zhao, Shuangtao [2 ]
Jiang, Changying [1 ]
Yao, Yixin [1 ]
Murfin, Kelley Paige [1 ]
Grundman, Hadley [1 ]
Zhang, Liang [1 ]
Nomie, Krystle [1 ]
Wang, Linghua [2 ]
Wang, Michael [1 ,3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-131079
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1487
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Targeting Kinome Reprogramming for Overcoming Ibrutinib-Resistance (IR) in Mantle Cell Lymphoma (MCL)
    Zhao, Xiaohong
    Jiang, Huijuan
    Wang, Michelle
    Li, Tao
    Gao, Jing
    Lwin, Tint
    Ren, Yuan
    Sotomayor, Eduardo
    Shah, Bijal D.
    Tao, Jianguo
    BLOOD, 2018, 132
  • [42] IBRUTINIB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA AND MANTLE CELL LYMPHOMA
    McDermott, J.
    Jimeno, A.
    DRUGS OF TODAY, 2014, 50 (04) : 291 - 300
  • [43] Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment
    Zhang, Liang
    Newberry, Kate J.
    Wang, Michael
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2013, 9 (06) : 495 - 497
  • [44] IBRUTINIB PLUS PALBOCICLIB HAS EFFICACY IN MANTLE CELL LYMPHOMA
    不详
    CANCER DISCOVERY, 2019, 9 (03) : 318 - 318
  • [45] p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma
    Guan, Jiyu
    Huang, Dan
    Yakimchuk, Konstantin
    Okret, Sam
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (05) : 1090 - 1100
  • [46] Ibrutinib in Mantle Cell Lymphoma Patients: Analysis of the Czech Lymphoma Study Group
    Obr, Ales
    Klener, Pavel, Jr.
    Janikova, Andrea
    Mocikova, Heidi
    Belada, David
    Salek, David
    Jirkuvova, Andrea
    Papajik, Tomas
    Trneny, Marek
    BLOOD, 2021, 138
  • [47] Ibrutinib in refractory mantle cell lymphoma or relapsed data update
    Paillassa, Jerome
    HEMATOLOGIE, 2015, 21 (05): : 257 - 259
  • [48] Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
    Tam, Constantine S.
    Anderson, Mary Ann
    Pott, Christiane
    Agarwal, Rishu
    Handunnetti, Sasanka
    Hicks, Rodney J.
    Burbury, Kate
    Turner, Gillian
    Di Iulio, Juliana
    Bressel, Mathias
    Westerman, David
    Lade, Stephen
    Dreyling, Martin
    Dawson, Sarah-Jane
    Dawson, Mark A.
    Seymour, John F.
    Roberts, Andrew W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (13): : 1211 - 1223
  • [49] Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents
    Inamdar, Arati A.
    Goy, Andre
    Ayoub, Nehad M.
    Attia, Christen
    Oton, Lucia
    Taruvai, Varun
    Costales, Mark
    Lin, Yu-Ting
    Pecora, Andrew
    Suh, K. Stephen
    ONCOTARGET, 2016, 7 (30) : 48692 - 48731
  • [50] Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma
    Thus, Yvonne J.
    Eldering, Eric
    Kater, Arnon P.
    Spaargaren, Marcel
    LEUKEMIA, 2022, 36 (09) : 2165 - 2176
12345